The FDA last week approved...

...Roche's phase 3 trial of its interleukin-6 inhibitor, Actemra, in COVID-19 patients that have been hospitalized with pneumonia. The drug was already used to treat coronavirus patients in China. The drugmaker also said it has added 10,000 vials of Actemra to the Strategic National Stockpile. The intravenous form of Actemra is covered under the pharmacy benefit for 25% of insured lives, and under the medical benefit for 21% of lives. 37% of all covered lives have access to Actemra under both the pharmacy and medical benefit.

SOURCE: MMIT Analytics, as of 3/30/20